Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 4 | 2012 | 93 | 0.340 |
Why?
|
| Esophageal Neoplasms | 4 | 2012 | 321 | 0.300 |
Why?
|
| Precancerous Conditions | 3 | 2012 | 196 | 0.250 |
Why?
|
| Alcoholism | 1 | 2005 | 172 | 0.240 |
Why?
|
| Hydrocortisone | 1 | 2005 | 298 | 0.240 |
Why?
|
| Stress, Psychological | 1 | 2005 | 313 | 0.220 |
Why?
|
| Prostatectomy | 5 | 2008 | 471 | 0.210 |
Why?
|
| Foot Diseases | 1 | 2021 | 12 | 0.200 |
Why?
|
| Telemedicine | 2 | 2021 | 169 | 0.200 |
Why?
|
| Ankle | 1 | 2021 | 20 | 0.200 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| Robotics | 4 | 2008 | 267 | 0.200 |
Why?
|
| Orthopedics | 1 | 2021 | 124 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2020 | 176 | 0.170 |
Why?
|
| Esophagoscopy | 2 | 2009 | 87 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2020 | 207 | 0.170 |
Why?
|
| Perioperative Care | 1 | 2020 | 161 | 0.170 |
Why?
|
| Laparoscopy | 5 | 2008 | 754 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 378 | 0.150 |
Why?
|
| Erectile Dysfunction | 2 | 2008 | 74 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 1169 | 0.140 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 1721 | 0.140 |
Why?
|
| Carmustine | 2 | 2005 | 70 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 426 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 462 | 0.130 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2005 | 118 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2010 | 2438 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2005 | 138 | 0.130 |
Why?
|
| Guanine | 2 | 2005 | 208 | 0.130 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2207 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 827 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2010 | 878 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 806 | 0.110 |
Why?
|
| Lymphoma | 2 | 2010 | 262 | 0.100 |
Why?
|
| Esophagectomy | 2 | 2009 | 84 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 7993 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2009 | 2261 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 46 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2010 | 55 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 98 | 0.090 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 80 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 84 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 436 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 232 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1961 | 0.080 |
Why?
|
| Sural Nerve | 1 | 2007 | 19 | 0.080 |
Why?
|
| Urination Disorders | 1 | 2008 | 50 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 252 | 0.080 |
Why?
|
| Aged, 80 and over | 8 | 2010 | 6509 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 373 | 0.080 |
Why?
|
| Quinazolines | 1 | 2008 | 220 | 0.070 |
Why?
|
| Humans | 20 | 2021 | 86643 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 468 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2009 | 1939 | 0.070 |
Why?
|
| Middle Aged | 13 | 2010 | 25028 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2010 | 1538 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2008 | 2501 | 0.070 |
Why?
|
| Male | 14 | 2010 | 40965 | 0.070 |
Why?
|
| Adult | 10 | 2010 | 25648 | 0.070 |
Why?
|
| Neoplasms | 1 | 2020 | 2898 | 0.070 |
Why?
|
| Arousal | 1 | 2005 | 170 | 0.060 |
Why?
|
| Social Environment | 1 | 2005 | 188 | 0.060 |
Why?
|
| Aged | 10 | 2010 | 18415 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2009 | 3640 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 383 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 589 | 0.060 |
Why?
|
| Prostate | 1 | 2007 | 378 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2009 | 235 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 674 | 0.060 |
Why?
|
| Probability | 3 | 2009 | 355 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 371 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1376 | 0.060 |
Why?
|
| Ethanol | 1 | 2005 | 249 | 0.060 |
Why?
|
| Motivation | 1 | 2005 | 287 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 636 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 943 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1076 | 0.050 |
Why?
|
| Organ Size | 3 | 2007 | 364 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 3679 | 0.050 |
Why?
|
| Melanoma | 1 | 2005 | 459 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1823 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 32 | 0.050 |
Why?
|
| Physicians | 1 | 2008 | 673 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 164 | 0.050 |
Why?
|
| Female | 9 | 2010 | 44532 | 0.050 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1075 | 0.040 |
Why?
|
| Mucous Membrane | 2 | 2009 | 83 | 0.040 |
Why?
|
| Hyperplasia | 2 | 2009 | 148 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2008 | 4213 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 328 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2009 | 237 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2009 | 2767 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 427 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 359 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2262 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1686 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 999 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1753 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 1531 | 0.030 |
Why?
|
| Prevalence | 2 | 2009 | 1239 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 2360 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 5210 | 0.030 |
Why?
|
| Biopsy | 2 | 2007 | 1163 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1673 | 0.030 |
Why?
|
| Microvessels | 1 | 2012 | 70 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2009 | 8489 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2010 | 68 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 83 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 218 | 0.020 |
Why?
|
| Quality of Life | 2 | 2008 | 1585 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 215 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 135 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 271 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 183 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 229 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 307 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 90 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 131 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 373 | 0.020 |
Why?
|
| Taxoids | 1 | 2008 | 129 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 196 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 5976 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 462 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 348 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 286 | 0.020 |
Why?
|
| Awareness | 1 | 2008 | 93 | 0.020 |
Why?
|
| Leukemia | 1 | 2009 | 320 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 365 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 996 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 379 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 722 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 153 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1540 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 486 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 364 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 612 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 596 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 623 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 859 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2010 | 628 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 171 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 185 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2008 | 485 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 90 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 229 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 353 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 248 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 332 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1197 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 270 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 196 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1863 | 0.020 |
Why?
|
| Mice | 2 | 2010 | 11352 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 930 | 0.020 |
Why?
|
| Body Weight | 1 | 2005 | 459 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 916 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1851 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 1186 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 1621 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1801 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1056 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1230 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1464 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 1241 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 1170 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 3092 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 26582 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 8981 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5417 | 0.010 |
Why?
|